Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/emtricitabine/tenofovir alafenamide - Mylan

Drug Profile

Dolutegravir/emtricitabine/tenofovir alafenamide - Mylan

Latest Information Update: 01 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mylan
  • Class 3-ring heterocyclic compounds; Adenine nucleotides; Amides; Antiretrovirals; Deoxyribonucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

  • 01 Jul 2019 Chemical structure information added
  • 20 Feb 2018 Preregistration for HIV infections in USA (PO) before February 2018
  • 20 Feb 2018 US FDA issues tentative approval to dolutegravir/emtricitabine/tenofovir alafenamide 50mg/200mg/25mg tablets for the treatment of HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top